These results support the EORTC QLQ-C30 as a reliable and valid measure of the quality of life of cancer patients in multicultural clinical research settings. Work is ongoing to examine the performance of the questionnaire among more heterogenous patient samples and in phase II and phase III clinical trials.

No abstract

Despite recognition that pain management is an important component in the treatment of Japanese cancer patients, progress in this area has been slowed by the lack of an appropriate measure of pain. In a prospective, single-institution study, a Japanese translation of the Brief Pain Inventory (BPI-J) was administered to 121 patients to assess the intensity and impact of cancer-related pain. After an analysis of the instrument's reliability and validity, this study tested the utility of the new measure in an analysis of the adequacy of analgesic prescription. Results were compared with predictive models from studies using non-Japanese patient groups. Factor analysis of the BPI items resulted in two factors, pain severity and pain interference, showing consistency with other language versions of the tool. Coefficient alphas of greater than 0.80 for the items comprising these two subscales indicate a reliable self-report pain instrument. After establishing the validity and reliability of the BPI-J, we examined possible predictors of inadequate pain management in these Japanese cancer patients. Similar to studies done in other countries, women patients and those whose pain severity was underestimated by their physician were more likely to be undermanaged for pain. The results of this study support the utility of the Japanese BPI for studies of the epidemiology of cancer pain in Japan, as well as for the assessment of pain treatment outcome in Japanese-speaking patients.

The results suggest that controlled-release oxycodone tablets offered stable and adequate pain control within a short period of time in most Japanese cancer patients who have not been taking opioid analgesics, and could be effectively titrated against pain from a starting dose of 5 mg every 12 h. This indicates that a lower strength controlled-release oxycodone formulation may make it possible to start and titrate the dose more appropriately and carefully in patients who are sensitive to opioid analgesics.

No abstract